At #VRBPAC today I made note of 2 interesting back-to-back comments made by panelists in regard to Moderna's proposed #vaccine in 6 month-5 yr olds.
I'll let Dr Meissner & Dr Portnoy speak for themselves.
I hope media captures nuances.
From 6:11:48-6:17:40
There are also comments like this one, parapharased (typos and all) by Dr Gans.
I'm not saying it's easy to extract the entirety of these full adcomm days, but I also feel like I see a bit of oversimplification, esp. if it doesn't follow an easy narrative.
At my old gig for 9 yrs I watched 100's of advisory committees. For most of those yrs I transcribed every single voting comment. It's a hard habit to break, I think because seeing comments in writing, in full, made me appreciate how nuanced even a one-sided/unanimous vote can be.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Each discussion Q could be posed as a vote, to make the Jun 28 VRBPAC more productive. Instead FDA goes w/ a single, overly broad voting Q that seems primed for a unanimous vote. VRBPAC politics are disheartening. The goal isn't a unanimous vote but a poll and the clearest input.
Yes, members will still get to speak in discussion, but w/out a vote for each, the outcome is less likely covered fully by most of media, who hasn't well been messaging their nuanced input.
This said, unfortunately my life is pulling me away from covering this mtg to much degree.
I can always do a post-mortem later. It's just a struggle to make this next meeting a priority with what else is going on for me right now.
I want FDA+gov to compile & release iron-clad info backed by detailed data & sourcing that stand on its own. I don’t want them policing info by Americans whose right is to take a view. Untruths are best counteracted by high-quality, truthful, transparent info which is enough work
Don’t pile on new work that FDA isn’t equipped for. Don’t have them delving into political issues when people are concerned about political influence on FDA.
Btw iron-clad info can look like conclusions from imperfect data sets that describes the limitations & weaknesses inherent
Woah, looks like a few key #VRBPAC members who've been participating in past FDA AdCom meetings for COVID vaccines had terms that ended yesterday: Kurilla, Meissner, & Offit. These are standouts. There may be more members, but I haven't had a chance to compare all w/ ended terms.
However, I believe that they can be brought in to serve as temporary members. The panel makeup will be interesting to follow. Here's the current standing #VRBPAC roster: fda.gov/advisory-commi…
Monto (the prior VRBPAC Chair) isn't on the standing roster page anymore. I wonder when his term expired?